Nuvalent (NUVL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual Meeting scheduled for June 16, 2026, with voting available online or virtually at 2:00 PM ET.
Shareholders are encouraged to review proxy materials and vote on key proposals by June 15, 2026.
Voting matters and shareholder proposals
Election of two Class II director nominees: Michael L. Meyers, M.D., Ph.D., and Ron Squarer, both recommended by the board.
Advisory vote to approve compensation for named executive officers.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends both director nominees for election to Class II positions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Nuvalent
- Q1 2026 net loss was $109.3M as lead oncology programs reached NDA stage and cash stood at $1.3B.NUVL
Q1 20267 May 2026 - Proxy covers director elections, executive pay, auditor ratification, and governance highlights.NUVL
Proxy filing28 Apr 2026 - Pivotal NSCLC data and FDA filings set stage for commercial launches and global expansion.NUVL
44th Annual J.P. Morgan Healthcare Conference14 Apr 2026 - Pivotal data and regulatory progress position the pipeline for major NSCLC market impact.NUVL
Corporate presentation13 Apr 2026 - Strong clinical data and rapid enrollment position ROS1 and ALK drugs for global launch.NUVL
Leerink Global Healthcare Conference 20269 Mar 2026 - Lead oncology assets near approval, targeting major lung cancer markets with strong trial momentum.NUVL
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Lead oncology assets deliver strong efficacy and safety, targeting multi-billion dollar markets.NUVL
Corporate presentation27 Feb 2026 - $1.4B cash runway into 2029; NDA filings and commercial launch prep for key oncology assets in 2026.NUVL
Q4 202526 Feb 2026 - Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion.NUVL
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026